Iceland· IS-EU/1/21/1594/001
Rybrevant
A amivantamab product containing amivantamabum inn, registered in Iceland by Janssen-Cilag International NV*. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Amivantamab is registered in 15 of 19 countries.
Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Amivantamab · ATC L01FX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amivantamab costs, country by country.
Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amivantamab · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$335.64
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Amivantamabum INN
- Manufacturer
- Janssen-Cilag International NV*
- Country
- Iceland (IS)
- ATC code
- L01FX18
- ATC class
- Amivantamab
- Defined daily dose
- 75 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amivantamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRybrevant 350 mgJanssen-Cilag International
- CzechiaRYBREVANTJanssen-Cilag International N.V., Beerse
- FinlandRybrevantJanssen-Cilag International NV
- IrelandRybrevant 350 mg concentrate for solution for infusionJanssen-Cilag International NV
- PolandRybrevantJanssen-Cilag International N.V.
- SwedenRybrevant 350 mg Koncentrat till infusionsvätska, lösningJanssen-Cilag International NV
- NorwayRybrevantJanssen-Cilag International N.V.
- NetherlandsRybrevant 1600 mg, oplossing voor injectieJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Rybrevant
- Norway · Rybrevant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/65451061-8a8f-4e90-8b18-1e09e240b595 GET /v1/drugs/65451061-8a8f-4e90-8b18-1e09e240b595?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX18",
"marketed": true,
"strength": "350 mg",
"ma_number": "EU/1/21/1594/001",
"substance": "Amivantamabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "44539"
}See everything about amivantamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.